The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
Fiona J DoreCleyton C DominguesNeeki AhmadiNabanita KunduYana KropotovaSara HoustonCarol RouphaelAytan MammadovaLinda WitkinAnamil KhiyamiRichard L AmdurSabyasachi SenPublished in: Cardiovascular diabetology (2018)
Saxagliptin, in combination with metformin, can help improve endothelial dysfunction in early diabetes before macrovascular complications appear. Trial registration Trial is registered under clinicaltrials.gov, NCT02024477.
Keyphrases
- type diabetes
- end stage renal disease
- cardiovascular disease
- study protocol
- phase iii
- glycemic control
- newly diagnosed
- clinical trial
- ejection fraction
- phase ii
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- metabolic syndrome
- insulin resistance
- adipose tissue
- cancer therapy
- drug delivery
- weight loss